Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026)

Enanta Pharmaceuticals (ENTA) has 8 years of Operating Leases data on file, last reported at $52.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 6.65% year-over-year to $52.8 million; the trailing twelve-month figure through Mar 2026 stood at $52.8 million (down 6.65% YoY), and the FY2025 full-year result was $54.8 million, up 1.51% from the prior year.
• Operating Leases for Q1 2026 stood at $52.8 million, down from $53.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $56.5 million in Q1 2025 and bottomed at $15.1 million in Q1 2022.
• The 5-year median for Operating Leases is $43.4 million (2024), against an average of $37.9 million.
• The widest annual swing landed in 2022, when Operating Leases surged 1886.86%; it then dropped 6.65% in 2026.
• A 5-year view of Operating Leases shows it stood at $21.9 million in 2022, then decreased by 6.11% to $20.5 million in 2023, then jumped by 175.06% to $56.5 million in 2024, then decreased by 4.73% to $53.8 million in 2025, then declined by 1.87% to $52.8 million in 2026.
• The last three Operating Leases figures came in at $52.8 million (Q1 2026), $53.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.

Peer Comparison